Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00940992 · ClinicalTrials.gov registry record · Phase 2
A Study of DER 45-EV Gel to Treat Rosacea
A Phase 2 study of Rosacea, sponsored by Sol-Gel Technologies.
- Completed
- Registry status
- Phase 2
- Development phase
- 92
- Enrollment target
- 10
- Study locations
NCT00940992: Completed Phase 2 study of Rosacea, sponsored by Sol-Gel Technologies.
NCT00940992 is a Phase 2 study of Rosacea that has completed, run by Sol-Gel Technologies. The registered enrollment target is 92 participants, below the 239-participant average among 23 other Rosacea trials with a reported enrollment target (62% lower). The trial reports 10 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00940992, a Phase 2 study of Rosacea, has completed, sponsored by Sol-Gel Technologies.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 92 participants
- Enrollment target
- 10
- Study locations
Study Summary
To identify lowest efficacious dose of DER 45 EV Gel, 1% and 5% verses vehicle in patients with rosacea.
Primary Outcome
The proportions of subjects with the primary measure of success at week 12 /end of study ,defined as a 2-grade improvement in the IGA (Investigator Global Assessment) relative to Baseline. The Investigator Global Assessment grades are: Grade 0 (Clear), Grade 1 (Almost Clear), Grade 2 (Mild), Grade 3 (Moderate) and Grade 4 (Severe).
Conditions Studied
Interventions
- DRUG Vehicle
- DRUG DER 45 EV
Study Locations (10)
Florida
- Baumann Cosmetic & Research Institute - Miami
- FXM Research Corp - Miami
Texas
- DermResearch, Inc - Austin
- J & S Studies, Inc - College Station
Georgia
- Augusta Centre for Dermatology and Skin - Augusta
Minnesota
- Minnesota Clinical Study Center - Fridley
New York
- Skin Search of Rochester, Inc - Rochester
Tennessee
- Tennessee Clinical Research Center - Nashville
Washington
- Premier Clinical Research - Spokane
Wisconsin
- Madison Skin and Research, Inc - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 92 participants |
| Start Date | 2012-01 |
| Est. Completion | 2013-01 |
| Phase | Phase 2 |
What the finished NCT00940992 record still lists
NCT00940992 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 92 participants, a relatively small participant target, below the 239-participant average among 23 other Rosacea trials with a reported enrollment target (62% lower).
The record links to 1 condition, with Rosacea appearing as the primary indexed condition, and to 2 interventions - of which Vehicle is the first listed.
NCT00940992 lists 10 locations in 8 states (Florida, Texas, Georgia).
Frequently Asked Questions
What is clinical trial NCT00940992 about?
NCT00940992 is a clinical study titled "A Study of DER 45-EV Gel to Treat Rosacea". To identify lowest efficacious dose of DER 45 EV Gel, 1% and 5% verses vehicle in patients with rosacea.
What is the current status of trial NCT00940992?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 92 participants. The study started on 2012-01. Estimated completion is 2013-01.
What conditions does trial NCT00940992 study?
This clinical trial studies the following conditions: Rosacea.
What interventions are being tested in trial NCT00940992?
The interventions under investigation include: Vehicle (DRUG), DER 45 EV (DRUG).
Who is sponsoring clinical trial NCT00940992?
This trial is sponsored by Sol-Gel Technologies, which has 15 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00940992 being conducted?
This trial has 10 study locations across Florida, Georgia, Minnesota, New York, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Rosacea
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00940992's enrollment target sits among peer trials
92 13th of 23 higher than 11 of 23 other Rosacea trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Rosacea trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluating Use of Topical Imipramine and Amitriptyline in Reducing Ultraviolet B Light-Induced Redness in Patients With Rosacea
RECRUITING · Phase 2
-
Rosacea and Ivermectin
COMPLETED · Phase 2
-
AGN-199201 for the Treatment of Erythema With Rosacea
COMPLETED · Phase 2
-
Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea
COMPLETED · Phase 2
-
Effects of Oral Supplement Containing L-Histidine and Antioxidants on the Skin Barrier Function and Systemic Inflammation in Rosacea
RECRUITING · NA
-
The Use of Image-Based Computer Gradings in the Analysis of Acne, Rosacea, Melasma, and Seborrheic Dermatitis
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03184545 · 92 participants · Phase 3
Comparing the Outcome of Electrical Stimulation and Physical Therapy in Patellofemoral Pain Syndrome
- NCT04172532 · 92 participants · Phase 1
Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer
- NCT04508088 · 92 participants
Skeletal Health and Bone Marrow Composition in Newly Diagnosed Adolescents With Crohn Disease
- NCT04840602 · 92 participants · Phase 2
Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia